All In Biotech

Drug Trial Radar · NCT07006727

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Oct 16, 2025

Primary completion

Aug 29, 2031

Study completion Aug 29, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.

Conditions

  • Small Cell Lung Carcinoma
  • Large Cell Neuroendocrine Carcinoma of the Lung
  • Neuroendocrine Prostate Cancer
  • Gastroenteropancreatic Neuroendocrine Carcinoma
  • Non-prostate Extrapulmonary Neuroendocrine Carcinoma
  • Cervical Neuroendocrine Carcinoma
  • Thymic Neuroendocrine Carcinoma
  • Genitourinary Neuroendocrine Carcinoma
  • Unknown Primary Neuroendocrine Carcinomas
  • Merkel Cell Carcinoma
  • Medullary Thyroid Carcinoma

Interventions

  • 225Ac-ETN029Drug

    Radioligand therapy

  • 111In-ETN029Drug

    Radioligand imaging agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with dose limiting toxicities of 225Ac-ETN029Time frame: From the start of study treatment until 6 weeks after
  2. Incidence and severity of adverse events and serious adverse events of 225Ac-ETN029Time frame: From start of study treatment until completion of the 36 month follow up, assessed up to approximately 42 months
  3. Dose modifications for 225Ac-ETN029Time frame: From the start of study treatment until last dose of study treatment, assessed as approximately 24 weeks
  4. Dose intensity for 225Ac-ETN029Time frame: From start of study treatment until last dose of study treatment, assessed as approximately 24 weeks

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • University Of Iowa

    Iowa City, Iowa · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Corewell Health William Beaum Hosp

    Royal Oak, Michigan · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Recruiting

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan · Recruiting

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Seoul, Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.